SCHEMBL26326385

SCHEMBL26326385

Cc1cc(I)cc(C(N)=S)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
C1S P09871 1/20 0.41
PRSS3 P35030 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.38
TPMT P51580 1/20 0.33
HTT P42858 1/20 0.33
PARP1 P09874 1/20 0.32
TTR P02766 1/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 3/20 0.31
GAA P10253 2/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
PKM P14618 1/20 0.30
HSD17B10 Q99714 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3371815 0.84 PRSS1 (0.56) PRSS1PRSS2C1SPRSS3SMN1; SMN2
SCHEMBL12130408 0.75 ASH1L (0.38) SMN1; SMN2HTTTTRCYP1A2POLB
SCHEMBL16960603 0.75 TPMT (0.37) PRSS1PRSS2C1SPRSS3TPMT
SCHEMBL12332467 0.74 CTSL (0.42) PRSS1PRSS2C1SPRSS3SMN1; SMN2
SCHEMBL12876024 0.74 SMN1; SMN2 (0.42) PRSS1PRSS2C1SPRSS3SMN1; SMN2
SCHEMBL16925558 0.71 TPMT (0.70) SMN1; SMN2TPMTMAPTKDM4ELMNA
SCHEMBL12127561 0.71 ALDH1A1 (0.42) PRSS1PRSS2C1SPRSS3SMN1; SMN2
SCHEMBL12128276 0.69 CTSL (0.47) PRSS1PRSS2C1SPRSS3GAA
SCHEMBL21588074 0.69 SMN1; SMN2 (0.31) SMN1; SMN2
SCHEMBL812374 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303530-A1 COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XWPharma Ltd. (KY) 2023-09-28 US disclosed
US-11767313-B2 Compounds as nuclear transport modulators and uses thereof XWPharma Ltd. (KY) 2023-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767313-B2 Compounds as nuclear transport modulators and uses thereof XPOT, XPO1, XPO5 PRSS1 4325/4885PRSS2 4758/4885C1S 4848/4885
US-20230303530-A1 COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPOT, XPO1, XPO5 PRSS1 4325/4885PRSS2 4758/4885C1S 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.